Plasma Heat Shock Protein 90 Levels in Patients with Spondyloarthritis and Their Relation to Structural Changes: A Cross-Sectional Study
Kristýna Bubováa b, Hana Štorkánováa b c, Sabína Oreskáa b c, Maja Špiritovićb d e f, Barbora Heřmánkovád e, Katerina Mintalovab, Monika Gregováa b c, Markéta Hušákováa b c, Jana Horinkovaa b c, Šárka Forejtováa b c, J Gatterováa b c, Jiří Štolfaa b c, Martin Komarce g, Jiří Vencovskýa b c, Karel Pavelkáa b c, Ladislav Šenolta b c, Michal Tomčíka b
- aDepartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- bInstitute of Rheumatology, Prague, Czech Republic
- cInstitute of Rheumatology, Prague, Czech RepublicDepartment of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
- dDepartment of Physiotherapy, Faculty of Physical Education &
- eSport, Charles University, Prague, Czech Republic
- fInstitute of Rheumatology, Prague, Czech RepublicDepartment of Physiotherapy, Faculty of Physical Education & Sport, Charles University, Prague, Czech Republic
- gDepartment of Methodology, Faculty of Physical Education &
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Aim: Heat shock protein 90 (Hsp90) is a molecular chaperone regulating immune response. We aimed to assess systemic Hsp90 as a biomarker for spondyloarthritis (SpA). Materials & methods: Total of 80 axial SpA (axSpA) and 22 psoriatic arthritis patients and a corresponding number of age- and sex-matched healthy controls (HC) were included. Plasma Hsp90 levels were measured by ELISA. Results: Hsp90 was significantly increased in axSpA patients compared with HC (median interquartile range: 15.7 [10.5–19.8] vs 8.3 [6.6–11.8] ng/ml, p < 0.001). Moreover, Hsp90 was superior to C-reactive protein in differentiating axSpA (and both radiographic axSpA [r-axSpA] and nonradiographic-axSpA) from HC. Hsp90 levels correlated with bone marrow edema of sacroiliac joints in r-axSpA patients (r = 0.594, p = 0.019). Conclusion: Hsp90 could become a biomarker for active inflammation in r-axSpA, and can better distinguish axSpA patients from healthy subjects than C-reactive protein.
TL;DRHsp90 could become a biomarker for active inflammation in r-axSpA, and can better distinguish axSpA patients from healthy subjects than C-reactive protein. (Semantic Scholar)